![Country [Change]](http://images.sciex.com/shared/icons/globe-white.png){kind=icon}
Country [Change]
Shop
Partners
AB Sciex is doing business as SCIEX. © 2010-2018 AB Sciex. The trademarks mentioned herein are the property of the AB Sciex Pte. Ltd. or their respective owners. AB SCIEX™ is being used under license. Beckman Coulter® is being used under license. Product(s) may not be available in all countries. For information on availability, please contact your local representative. For research use only. Not for use in diagnostic procedures.
Currently, there are 3 main types of in vitro transcribed (IVT) RNA drugs. Two of these—conventional messenger RNA (mRNA) and base-modified mRNA (bmRNA), which incorporates chemically modified nucleotides—are non-replicating. The third type is self-replicating RNA (srRNA), which is based on an engineered viral genome but devoid of viral structural protein genes. Its self-replicating ability makes srRNA a promising tool for new therapeutic drugs.
What better to learn how a new technology like icIEF-UV/MS is advancing drug development than hearing from the labs that are using it?
We know that LC-MS oligonucleotide analysis can have its share of challenges—challenges with sensitivity, challenges with adduct formation and challenges with data analysis, to name just a few. That’s why this blog takes a closer look at the dos and don’ts of this type of analysis and explores some keys to success. It also explains why following these simple rules can vastly improve your oligonucleotide characterization and quantitation efficiency and success.
N-nitrosamine analysis has raised significant concerns in the pharmaceutical industry since 2018, when these potential carcinogens were found in several angiotensin II receptor blockers (sartans). Subsequent discoveries in ranitidine and some slow-release metformin medications prompted widespread product recalls. The industry has implemented stricter manufacturing requirements and intensified efforts to evaluate and control N-nitrosamine contamination. To meet stringent regulatory requirements, it is essential to develop effective chromatography and mass spectrometry (MS) methods for N-nitrosamine analysis. This blog addresses the challenges associated with detecting N-nitrosodimethylamine (NDMA) in metformin drug products.
In today’s rapidly evolving technological landscape, businesses heavily rely on software and IT systems to drive their operations. However, the pursuit of efficiency and speed often leads to the accumulation of what is known as technical debt. Technical debt refers to the implied cost incurred when businesses choose quick but limited solutions over better approaches that may take more time to implement. This blog post will delve into the concept of technical debt, its implications for businesses and how to avoid falling victim to its detrimental effects.
On June 12, 2023, during a webinar hosted by New Food, Lin Qingsong—Principal Research Fellow and Director of the Protein and Proteomics Centre at the National University of Singapore—discussed the latest considerations related to risk assessment of alternative proteins.
Investing in a new LC-MS system is not an easy decision, especially if you have a range of analytical requirements in your laboratory. This blog is part of a series intended to help you choose the right system for your pharmaceutical research and development needs.
Bringing a new drug to market is a costly and complex process. With potentially hundreds of thousands of new compounds to screen during drug discovery, sample throughput is a common bottleneck for pharmaceutical companies. So how do you overcome this barrier?
So, you need a new liquid chromatography-mass spectrometry (LC-MS) system for your metabolite identification (metID) studies, and you are not sure which option is right for you. This blog provides an overview of the metID solutions offered by SCIEX, so you can make the best decision for your organization.
At SCIEX, we are proud to provide analytical systems to the pharmaceutical industry. We work hard to understand the demands of analytical work and the processes required to develop and manufacture drugs.
Contact Support